Prostate Cancer Clinical Trials in New Haven, Connecticut

10 studies are recruiting for prostate cancer in New Haven, Connecticut right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

   This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma [cutaneous/acral], squamous cell carcinomas of the head and neck (SCCHN), HER2-negative gastric can…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Yale Cancer Center, New Haven, Connecticut

   Locations

   90 in total

   Run by

   Daiichi Sankyo

   See if you can join NCT06172478 on ClinicalTrials.gov

2. A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

   Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer (mCRPC). Researchers have designed a study medicine called ifinatamab deruxtecan (also called I-DXd or MK-2400) to treat mCRPC. The goal of this study is to learn if people who receive I-DXd live longer ov…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Yale-New Haven Hospital-Yale Cancer Center ( Site 0050), New Haven, Connecticut

   Locations

   298 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06925737 on ClinicalTrials.gov

3. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

   The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, toler…

   Stage

   Phase 1

   Ages

   12 and older

   Site

   Yale Cancer Center, New Haven, Connecticut

   Locations

   77 in total

   Run by

   PMV Pharmaceuticals, Inc

   See if you can join NCT04585750 on ClinicalTrials.gov

4. The SUGAR Study; SBRT and Relugolix) for Prostate Cancer

   The goal of this clinical trial is to measure the toxicity and effectiveness of the following treatments for cFIR/cgUIR prostate cancer patients. Stereotactic body radiotherapy (SBRT) alone or Stereotactic body radiotherapy (SBRT) combined with Ultrashort GNRH Antagonist called Relugolix (an oral d…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Yale Cancer Center, New Haven, Connecticut

   Locations

   4 in total

   Run by

   Yale University

   See if you can join NCT06111781 on ClinicalTrials.gov

5. Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

   The overall aim of the trial is to evaluate the safety, tolerability, and pharmacokinetics (PK) of AMG 509 (monotherapy and in combination with abiraterone acetate and enzalutamide) and to evaluate preliminary efficacy. As of Protocol Amendment 10 (09 July 2025), only Parts 4A expansion, 6, and 7 a…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Yale New Haven Hospital, New Haven, Connecticut

   Locations

   57 in total

   Run by

   Amgen

   See if you can join NCT04221542 on ClinicalTrials.gov

6. FOG-001 in Locally Advanced or Metastatic Solid Tumors

   The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Yale University School of Medicine, New Haven, Connecticut

   Locations

   33 in total

   Run by

   Parabilis Medicines, Inc.

   See if you can join NCT05919264 on ClinicalTrials.gov

7. Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

   This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX007 in adults with metastatic castration-resistant prostate cancer (mCRPC).

   Stage

   Phase 1

   Ages

   18 to 100

   Site

   Yale New Haven Hospital, New Haven, Connecticut

   Locations

   36 in total

   Run by

   Janux Therapeutics

   See if you can join NCT05519449 on ClinicalTrials.gov

8. A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer

   The purpose of this study is to find out whether tinengotinib in combination with abiraterone acetate and prednisone or enzalutamide is a safe treatment that causes few or mild side effects in people with metastatic castration-resistant prostate cancer (mCRPC).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Yale University (Data Collection Only), New Haven, Connecticut

   Locations

   12 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT06457919 on ClinicalTrials.gov

9. International Registry for Men With Advanced Prostate Cancer (IRONMAN)

   Our intent is to establish the International Registry to Improve Outcomes in Men with Advanced Prostate Cancer (IRONMAN) as a prospective, international cohort of minimum 5,000 men with advanced cancer, including men with mHSPC and M0/M1 CRPC. The goal is to establish a population-based registry an…

   Stage

   Not phased

   Ages

   21 and older

   Site

   Yale University, New Haven, Connecticut

   Locations

   121 in total

   Run by

   Prostate Cancer Clinical Trials Consortium

   See if you can join NCT03151629 on ClinicalTrials.gov

10. A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

    This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel reversible small molecule inhibitor of PARG.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Yale University, Yale Cancer Center, New Haven, Connecticut

    Locations

    14 in total

    Run by

    858 Therapeutics, Inc.

    See if you can join NCT06395519 on ClinicalTrials.gov